Adenovirus Clinical Trials

8 recruiting

Adenovirus Trials at a Glance

13 actively recruiting trials for adenovirus are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Columbus, Philadelphia, and Memphis. Lead sponsors running adenovirus studies include SymBio Pharmaceuticals, Columbia University, and Chimerix, Inc.

Browse adenovirus trials by phase

Treatments under study

About Adenovirus Clinical Trials

Looking for clinical trials for Adenovirus? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenovirus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenovirus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 3

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Adenovirus Infections
SymBio Pharmaceuticals180 enrolled61 locationsNCT07387367
Recruiting
Phase 1

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed+4 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT05101213
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting
Phase 2

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

AdenovirusCytomegalovirus
St. Jude Children's Research Hospital42 enrolled1 locationNCT05664126
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting
Phase 1Phase 2

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 2

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

AdenovirusPrimary Immune Deficiency Disorder
New York Medical College20 enrolled10 locationsNCT03266627
Recruiting
Phase 1Phase 2

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

Adenovirus Infection
Nationwide Children's Hospital12 enrolled1 locationNCT04722029
Recruiting
Phase 2

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Cytomegalovirus InfectionsAdenovirus InfectionEBV+2 more
University Hospital, Basel, Switzerland30 enrolled1 locationNCT02007356
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 2

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Adenovirus Infections
SymBio Pharmaceuticals52 enrolled11 locationsNCT04706923
Recruiting
Phase 3

Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection

Adenovirus
A.O.U. Città della Salute e della Scienza80 enrolled1 locationNCT06299813
Recruiting
Phase 1

A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects

Adenovirussmallpox
Chimerix, Inc40 enrolled1 locationACTRN12616001657415